Stanford Cancer Institute

Running trials

• Recruiting

  Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

  NCT07441681· Phase 3· NRG Oncology· Source

• Recruiting

  A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

  NCT07586202· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  NCT07489066· Phase 2· Pfizer· Source

• Recruiting

  Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  NCT07195734· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

  NCT07405801· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· BeOne Medicines· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

  NCT04119024· Phase 1· Anusha Kalbasi· Source

• Recruiting

  A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07111520· Phase 1/2· BioNTech SE· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· BeOne Medicines· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

• Recruiting

  A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  NCT06661915· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

  NCT06915753· Phase 1· Tyra Biosciences, Inc· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· NRG Oncology· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Active, not recruiting

  A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

  NCT06777316· Phase 1/2· Cogent Biosciences, Inc.· Source

• Recruiting

  Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

  NCT06475989· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  NCT06581406· Phase 2/3· Replimune, Inc.· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Recruiting

  A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

  NCT06343805· Phase 1· Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source

• Active, not recruiting

  Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

  NCT06538038· PrECOG, LLC.· Source

• Recruiting

  Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  NCT06422806· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

  NCT06449222· Phase 2· BioNTech SE· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Recruiting

  Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

  NCT06433947· Phase 1· Opna Bio LLC· Source

• Recruiting

  VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

  NCT06264180· Phase 3· Replimune, Inc.· Source

• Recruiting

  A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

  NCT06248515· Phase 2· Georgetown University· Source

• Recruiting

  A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

  NCT06150664· Phase 1· Compass Therapeutics· Source

• Active, not recruiting

  A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

  NCT06206837· Phase 1/2· Pfizer· Source

• Recruiting

  Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  NCT06162221· Phase 1/2· Revolution Medicines, Inc.· Source

• Active, not recruiting

  A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

  NCT06079879· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  NCT06034002· Phase 1· Incyte Corporation· Source

• Recruiting

  Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  NCT06128551· Phase 1/2· Revolution Medicines, Inc.· Source

• Recruiting

  Safety and Efficacy of OBX-115 in Advanced Solid Tumors

  NCT06060613· Phase 1/2· Obsidian Therapeutics, Inc.· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

  NCT06002828· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  NCT05929768· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

  NCT05602194· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

  NCT05907954· Phase 2· IDEAYA Biosciences· Source

• Active, not recruiting

  Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

  NCT05303792· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  FOG-001 in Locally Advanced or Metastatic Solid Tumors

  NCT05919264· Phase 1/2· Parabilis Medicines, Inc.· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

  NCT05878184· Phase 1· Sana Biotechnology· Source

Showing 50 of 155.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer13 recruiting
• Childhood cancers8 recruiting
• Melanoma7 recruiting
• Head and neck cancer6 recruiting
• Ovarian cancer5 recruiting
• Pancreatic cancer5 recruiting
• Endometrial cancer4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Prostate cancer4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Colorectal cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Bladder cancer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Hodgkin lymphoma2 recruiting
• Liver and biliary tract cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Myelodysplastic syndromes2 recruiting
• Thyroid cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting
• Sarcoma1 recruiting
• Thymoma and thymic carcinoma1 recruiting

Closed trials

• Withdrawn

  89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

  NCT05423197· Phase 2· Andrei Iagaru· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Completed

  "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

  NCT05410509· University of Alabama at Birmingham· Source

• Terminated

  Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

  NCT05984199· Phase 1/2· Vor Biopharma· Source

• Terminated

  Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

  NCT05609942· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

  NCT05902494· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Boehringer Ingelheim· Source

• Completed

  Study to Evaluate Percussive Ventilation Breathhold to Improve Lung Stereotactic Ablative Radiotherapy

  NCT05283564· Stanford University· Source

• Terminated

  Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

  NCT05537766· Phase 2· Kite, A Gilead Company· Source

• Completed

  A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

  NCT05082610· Phase 1· Hummingbird Bioscience· Source

• Terminated

  A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

  NCT05169489· Phase 1· Regeneron Pharmaceuticals· Source

• Completed

  Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

  NCT05282459· Phase 1/2· Tian Yi Zhang· Source

• Terminated

  Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

  NCT04849910· Phase 1/2· Vor Biopharma· Source

• Terminated

  Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

  NCT04892446· Phase 2· Gilead Sciences· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Gilead Sciences· Source

• Completed

  Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

  NCT04093596· Phase 1· Allogene Therapeutics· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

  NCT03746080· Phase 2· Lawrence D Recht· Source

• Completed

  (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

  NCT03580655· Phase 2· Blueprint Medicines Corporation· Source

• Terminated

  Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

  NCT03616470· Phase 3· GlycoMimetics Incorporated· Source

• Completed

  Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

  NCT03583086· Phase 1/2· Vanderbilt-Ingram Cancer Center· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source

• Completed

  Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554· Phase 2/3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

  NCT03424005· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466· Phase 3· Kite, A Gilead Company· Source

• Completed

  Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

  NCT03274687· Phase 3· NRG Oncology· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

  NCT03011372· Phase 2· Incyte Corporation· Source

• Completed

  Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

  NCT02844816· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

  NCT02254278· Phase 2· NRG Oncology· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

  NCT01224665· SWOG Cancer Research Network· Source

• Completed

  Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

  NCT01251861· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

  NCT00936390· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Myeloproliferative neoplasms9 works · 7 trials